Long title
An open-label, Phase I study to assess the safety of multiple doses of CYAD-101, administered after standard FOLFOX chemotherapy in patients with unresectable metastatic colorectal cancer (alloSHRINK-study-Standard cHemotherapy Regimen and Immunotherapy with allogeneic CYAD-101-based CYAD-101 Chimeric antigen receptor T-cells)
Date receipt dossier
EU record number
CYAD-N2L-101
EudraCT number
2018-000927-14
Company / Sponsor
Celyad
Phase
I
Treated organism
Humans
Indication category
Cancer therapy
Disease
Unresectable metastatic colorectal cancer
Therapeutic approach
Immunotherapy
Genetic modification
NKG2D-chimeric antigen receptor, the truncated CD19 tag and the TIM8 molecule which interferes with the interaction between the natural TCR and endogenous CD3ζ
Method of transfer of nucleic acid of interest
Moloney murine leukemia virus
Administered biological material
Allogeneic T cells retrovirally transduced with a chimeric antigen receptor based on the NKG2D receptor, the truncated CD19 tag and the TIM8 molecule which interferes with the interaction between the natural TCR and endogenous CD3ζ
Route of administration
Intravenous
Locations in Belgium
UZ Leuven, Institut Jules Bordet, Universitair ziekenhuis Antwerpen, UZ Gent
Type of procedure
Contained use only
Current status
Authorized
Pharmaceutical study code
CYAD-101